Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HPC, Cord Blood in Acute Ischemic Stroke
NCT03735277Phase 1Unknown
- Sponsor
- BHI Therapeutic Sciences
- Start
- Mar 2021
- Primary completion
- Jul 2022
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of hematopoietic progenitor cells, cord blood in ischemic stroke, sponsored by BHI Therapeutic Sciences. Primary endpoints: Adverse Events at 12 months and Graft Versus Host Disease at 12 months. Status: unknown.
02
Drugs
hematopoietic progenitor cells, cord blood
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT03735277.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03735277.